Contribution of front-line, standard-of-care drugs to bactericidal responses, resistance emergence, and cure in murine models of easy- or hard-to-treat tuberculosis disease
Antimicrobial Agents and Chemotherapy · 07.05.2025 · 69 (5)
DOI: 10.1128/aac.01901-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 07.05.2025. Verfasst von Nathan Peroutka-Bigus und 11 weiteren Autor:innen. Beteiligte Einrichtung: Mycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA. Hauptthemen laut MEDLINE: Pyrazinamide, Rifampin, Antitubercular Agents, Mycobacterium tuberculosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bill and Melinda Gates Foundation, Gates Foundation, NIAID NIH HHS.
Abstract (Originalsprache)
By assessing the standard-of-care regimen for tuberculosis (TB) in BALB/c and C3HeB/FeJ mice, we demonstrate that rifampin, with or without pyrazinamide, is essential for an effective bactericidal response and suppression of resistance. Potency measurements in an in vitro lipid-rich model and a rabbit caseum assay recapitulate the significance of rifampin as a sterilizing agent. These outcomes align with clinical performance, thus emphasizing the value of in vitro predictive tools and murine TB models with human-like pathology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Mycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.
- Department of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, Massachusetts, USA.
- Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.
- The Stuart B. Levy Center for Integrated Management of Antimicrobial Resistance, Boston, Massachusetts, USA.
- Department of Biomedical Engineering, Tufts University School of Engineering, Medford, Massachusetts, USA.
- Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
ORCID-Profile: Nathan Peroutka-Bigus, Radojka M Savic, Bree B Aldridge, Jansy P Sarathy, Gregory T Robertson
Förderung
- Bill and Melinda Gates Foundation
- Gates Foundation
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Peroutka-Bigus, N., Brooks, E. J., Ramey, M. E., D'Erasmo, H., Ernest, J. P., Bauman, A. A., Woolhiser, L. K., Savic, R. M., Lenaerts, A. J., Aldridge, B. B., Sarathy, J. P., & Robertson, G. T. (2025). Contribution of front-line, standard-of-care drugs to bactericidal responses, resistance emergence, and cure in murine models of easy- or hard-to-treat tuberculosis disease. Antimicrobial Agents and Chemotherapy, 69(5). https://doi.org/10.1128/aac.01901-24
Vancouver
Peroutka-Bigus N, Brooks EJ, Ramey ME, D'Erasmo H, Ernest JP, Bauman AA, et al. Contribution of front-line, standard-of-care drugs to bactericidal responses, resistance emergence, and cure in murine models of easy- or hard-to-treat tuberculosis disease. Antimicrobial Agents and Chemotherapy. 2025;69(5). doi:10.1128/aac.01901-24
BibTeX
@article{PeroutkaBigus2025,
author = {Peroutka-Bigus, Nathan and Brooks, Elizabeth J and Ramey, Michelle E and D'Erasmo, Hope and Ernest, Jackie P and Bauman, Allison A and Woolhiser, Lisa K and Savic, Radojka M and Lenaerts, Anne J and Aldridge, Bree B and Sarathy, Jansy P and Robertson, Gregory T},
title = {Contribution of front-line, standard-of-care drugs to bactericidal responses, resistance emergence, and cure in murine models of easy- or hard-to-treat tuberculosis disease},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
volume = {69},
number = {5},
doi = {10.1128/aac.01901-24}
}
EUVIMED